ProCE Banner Activity

My Thoughts on 2 Notable PTCL Studies From ASCO 2019

Clinical Thought
Get expert insights on key findings in PTCL from the 2019 ASCO annual meeting.

Released: July 22, 2019

Expiration: July 20, 2020

Share

Faculty

Steven M. Horwitz

Steven M. Horwitz, MD

Assistant Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Seagen

Faculty Disclosure

Primary Author

Steven M. Horwitz, MD

Assistant Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

Steven M. Horwitz, MD, has disclosed that he has received funds for research support from ADC Therapeutics, Aileron, Celgene, Forty Seven, Infinity/Verastem, Kyowa-Hakko-Kirin, Millennium/Takeda, Seattle Genetics, and Trillium and consulting fees from ADC Therapeutics, Affimed, Aileron, Angimmune, BeiGene, Corvus, Forty Seven, Infinity/Verastem, Innate Pharma, Kura, Kyowa-Hakko-Kirin, Merck, Millennium/Takeda, miRagen, Mundipharma, Portola, Seattle Genetics, and Syros.